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Abstract. Background. Isothiocyanates are constituents of cruciferous vegetables which have 
been associated with reduced cancer risk partially through their ability to induce apoptosis in 
malignant cells including melanoma. Materials and Methods: We have utilized human 
malignant melanoma (A375), epidermoid carcinoma (A431) and immortalized keratinocyte 
(HaCaT) cells exposed to various isothiocyanates, under different experimental conditions.  
Results: An experimental in vitro model utilizing low isothiocyanate concentrations (0.1-5 
μΜ for 48h with all treatments being refreshed after 24h) was shown to be (i) most efficient 
in exerting an anti-cancer effect when compared to higher concentrations (5-100 μΜ for 24 or 
48h added as a single bolus) and (ii) specific to A375 cells while A431 and HaCaT cells 
remained unaffected. Such effect involved the activation of several caspases including (iii) 
initiator caspases 8, 9, 4 (indicating the involvement of intrinsic, extrinsic and endoplasmic 
reticulum-based pathways) and (iv) effector caspases 3, 7 and 6.  
Conclusions: Utilization of low isothiocyanate concentrations (under conditions described 
herein) exerts an anti-cancer effect specific to human malignant melanoma cells and thus 
providing a therapeutic basis for their utilization in management of the disease.   
 
Malignant melanoma is the fifth most common cancer in UK with its incidence rates 
being continuously rising faster than any other malignancy (1). Epidemiological studies 
suggest that an increased dietary consumption of cruciferous vegetables can reduce cancer 
incidence. These effects can be attributed to the high levels of glucosinolates (GSLs) present 
which are sulphur-containing glycosides and precursors for a group of compounds called 
isothiocyanates (ITCs) (2). Briefly, upon mechanical disruption of the plant cell wall (e.g. by 
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chewing), the enzyme myrosinase is released which then catalyses the hydrolysis of GSLs to 
ITCs, with subsequent release of HSO4
- and D-glucose (3). Different GSLs can form different 
ITCs, since glucoraphanin acts as the precursor for sulforaphane (SFN), gluconasturtin for 
phenethyl isothiocyanate (PEITC) and glucotropaeolin for benzyl isothiocyanate (BITC) (4). 
There is much speculation as to how ITCs may exhibit their chemotherapeutic effects, but the 
likelihood is that multiple molecular events are responsible. Potential biochemical 
mechanisms include (i) inhibition of carcinogen activity via suppression of phase I enzymes 
in xenobiotic metabolism, (ii) stimulation of phase II enzymes and (ii) induction of apoptosis 
(5, 6). Despite many reports demonstrating ITCs’ effectiveness against different cancers there 
have been a limited number of studies investigating their ability to induce apoptosis in human 
malignant melanoma cells (7) which their results are dependent on the utilization of high 
concentrations of ITCs.  
In this study, we have aim to develop a novel experimental in vitro model based on 
the utilization of low ITC concentrations capable of inducing apoptosis in human malignant 
melanoma (A375) cells. For this reason, our objectives were to (i) establish an experimental 
model of exposure to various ITCs and, furthermore, to (ii) characterize ITCs’ anti-cancer 
activities by determining the induction of a number of caspases descriptive of various 
apoptotic pathways including those of intrinsic, extrinsic and ER-dependent origin. 
 
Materials and Methods 
Chemicals. SFN was obtained from Abcam (Cambridge, UK) whereas PEITC and BITC 
from Sigma-Aldrich (St. Louis, MO, USA). All compounds were dissolved in DMSO 
(Sigma-Aldrich) and stored at -20oC. DMED medium, trypsin, PBS, FBS, L-Glutamine and 
Penicillin/Streptomycin were obtained from Labtech International Ltd (East Sussex, UK). 
Resazurin sodium salt was supplied by Sigma-Aldrich. All chemicals were of analytical 
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grade and purchased from Sigma-Aldrich, Applichem (Darmstadt, Germany) and Invitrogen 
(Carlsbad, CA, USA). BSA was obtained from Biosera (Boussens, France). Protease inhibitor 
cocktail was obtained from Roche (Basel, Switzerland). PVDF membranes (0.45 and 0.2 μm) 
were purchased from Millipore (Bedford, MA, USA). The pre-stained pink protein ladder 
was from Nippon Genetics Europe (Dueren, Germany). Primary (anti-PARP, anti-procaspase 
3, anti-procaspase 6, anti-procaspase 7 and anti-lamin A/C) and horseradish peroxidase-
conjugated secondary antibodies were purchased from Cell Signalling Technology (Danvers, 
MA, USA) whereas anti-β-actin from Sigma-Aldrich and enhanced chemi-luminescence 
western blotting substrate kit from Pierce Thermo Scientific (Waltham, MA, USA). 
 
Cell culture and treatment protocols. A375 and A431 cells were purchased from Sigma-
Aldrich (St. Louis, MO, USA). HaCaT cells were a kind gift from Dr Sharon Broby (Dermal 
Toxicology and Effects Group; Centre for Radiation, Chemical and Environmental Hazards; 
Public Health England, UK). All cell lines were cultured in DMEM medium (10% FBS, 
2mM L-Glutamine and 1% Penicillin/Streptomycin) and maintained in a humidified 
atmosphere at 37oC and 5% CO2. SFN, PEITC, BITC or vehicle were added either as (i) a 
single bolus concentration ranging between 5-100 μΜ for 24 to 48h or (ii) at 0.1-5 μΜ for 
48h with all treatments being refreshed after 24h. 
  
Cell viability assay. Cells (5x103) were seeded in 100 μl of complete medium into 96-well 
plates and kept overnight in the incubator before they were treated with either one of the 
treatment protocols. Cell viability was assessed by using the Alamar blue assay where in 
brief, resazurin sodium salt was dissolved in PBS (1mg/ml final concentration) and 10 μl of 
reagent were added into each well of the 96-well plates. After 4h of incubation, fluorescence 
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intensity was measured at 560Exc/590Em nm by using a Spectramax M5 multi-mode plate 
reader (Sunnyvale, CA, USA).  
 
Caspase activity assay. The caspase family fluorometric substrate kit II plus from Abcam 
(Cambridge, UK) was used according to the manufacturer's instructions. Cell lysates were 
prepared and 150-200 μg of protein extracts were incubated with each respective substrate for 
1h at 37oC. Fluorescence intensity was monitored at 400Exc/505Emnm by using a Spectramax 
M5 multi-mode plate reader 
 
Preparation of cell lysates and protein determination. Cells (0.8x106) were plated in 100mm 
dishes and cultured overnight at 37oC. Next day, cells were treated with 0.1-5 μΜ of each 
ITC for 48h (with all treatments being refreshed after 24h) and then trypsinized, collected in 
micro-centrifuge tubes and washed twice with PBS. Cell pellets were lysed in lysis buffer 
(10mM HEPES at pH 7.9, 10mM KCl, 0.1mM EDTA, 1.5mM MgCl2, 0.2% NP40) and 
supplemented with a protease inhibitors’ cocktail (20mM β-glycerophosphate and 0.2mM 
Na3VO4). Then, they were left on ice while periodically vortexed over a 30 min period. Cell 
lysates were centrifuged at 14,000 x g for 15min at 4oC and supernatants were transferred in 
fresh tubes. Protein content was determined by utilizing the BCA protein assay from Thermo 
Scientific (Waltham, MA, USA) according to manufacturer's instructions. Protein extracts 
were stored at -20oC until usage. 
 
Western immunoblotting. Forty micrograms (40 μg) of cellular protein extracts were 
separated by SDS-polyacrylamide gels and transferred electrophoretically onto PVDF 
membranes (either 0.45 or 0.2 μm). The blots were blocked in 5% non-fat milk powder in 
TBST buffer (50mM Tris-HCl, 150mM NaCl at pH 7.6 and 0.1% Tween-20) for 2h at room 
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temperature. The membranes were incubated with the appropriate primary antibody (1:1000 
for anti-PARP, anti-procaspase 3, anti-procaspase 6, anti-procaspase 7, anti-lamin A/C and 
1:2000 for anti-β-actin) overnight at 4oC under agitation. Next day, the membranes were 
incubated with the appropriate (mouse or rabbit) horseradish peroxidase-conjugated 
secondary antibody (1:2000) for 1h at room temperature under agitation, after being washed 
three times with TBST. Membranes were washed three times with TBST and once with 
distilled water. Labeled protein bands were detected by utilizing enhanced chemi-
luminescence. 
 
Statistical analysis. Measurements for cell viability assays were performed in quintuplicate 
(n=5) while those for caspase activity assays in triplicates (n=3) and all values are expressed 
as mean ± standard error. Statistical analysis was performed by means of a Student t-test. A 
value of P<0.05 was considered statistically significant. 
 
Results 
The effect of three different ITCs (SFN, PEITC and BITC) was evaluated at a range of single 
bolus concentrations (5-100 μM) in both human A375 malignant melanoma (Figure 1A-C) 
and HaCaT immortalized keratinocyte cells (Figure 1D-F) after 24h and 48h of treatment. 
Addition of a single bolus of each ITC concentration statistically significantly decreased 
(P<0.05) both A375 and HaCaT cell viability levels in a concentration-dependent manner. 
More specifically, SFN decreased cell viability at 10 μM onwards (24-48h) in A375 (Figure 
1A) and HaCaT (Figure 1D) cells. PEITC also decreased cell viability levels but at a 
concentration of 25 μM onwards (24-48h) for A375 (Figure 1B) and 10 μM onwards (24-
48h) for HaCaT (Figure 1E) cells. BITC exerted the highest potency, as it induced a 
7 
 
significant reduction in cell viability levels at 5 μM onwards (24-48h) in both A375 (Figure 
1C) and HaCaT (Figure 1F) cells.  
When utilized an in vitro model of ITC treatment by subjecting human malignant 
melanoma (A375) and non-melanoma (A431) cells as well as human normal keratinocyte 
(HaCaT; control) cells to a range of low ITC concentrations (0.1-5 μM for 48h but being 
refreshed after an initial 24h of treatment) our data revealed that SFN and PEITC statistically 
significantly inhibited (P<0.05) cell viability levels at 5 μM in A375 cells only (Figure 2A 
and 2B respectively). However, at this concentration, cells exposed to SFN showed a more 
profound inhibitory effect on viability levels compared to PEITC (approximately 60% vs. 
80% respectively). Finally, treatment with BITC also, statistically significantly decreased 
(P<0.05) the viability levels at concentrations as low as 2.5 μΜ onwards in A375 and A431 
cells only. However, this effect was more profound in A375 cells where a 2.5 μΜ inhibition 
of cell viability was recorded to levels of ~70% which was further decreased to ~ 30% after 
treatment with 5 μM of BITC (Figure 2C).  
Finally, in order to investigate whether treatment with ITCs induces an apoptotic 
response in A375 cells, the activity levels of the initiator caspases 4, 8 and 9 were evaluated. 
Activation of these caspases is indicative of the involvement of various apoptotic pathways in 
a manner where caspase 8 involves the extrinsic (29), caspase 9 the intrinsic (30) and caspase 
4 the endoplasmic reticulum (ER)-dependent (31) pathways. Our data showed that treatment 
with BITC statistically significantly increased (P<0.05) the activity levels of all initiator 
caspases whereas this was the case only for caspase 9 in PEITC treated cells. Alternatively, 
treatment with SFN showed no statistically significant changes in the activity levels of any of 
the above-mentioned caspases (Figure 3A-C). Similarly, western blot analysis data indicate 
that each of the SFN, PEITC and BITC were responsible for inducing a statistically 
significant decrease (P<0.05) in protein expression levels of the effector procaspases 3 
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(Figure 3D) and 6 (Figure 3E) while for procaspase 7 this was the case only for BITC 
treatment (Figure 3F). Consequently, when these procaspases become activated they cleave 
specific cellular proteins including poly(ADP-ribose) polymerase (PARP) (Figure 3D) and 
lamins A and C (Figure 3E) such as in the case of procaspase 3 and 6, respectively. Overall, 
our results demonstrate that ITCs induce caspase activation in a manner which treatment with 
BITC results in the largest decrease in procaspase levels, followed by PEITC and SFN.  
 
Discussion 
The majority of various studies have utilized non-melanoma (8-14) and melanoma 
(15-19) experimental models based on a single bolus addition of large ITC concentrations 
where a wide range of biological effects were documented but without provision of 
appropriate control (non-tumorigenic) cells. Similarly, we have been able to document such 
anti-cancer activity in melanoma cells but also in control keratinocyte cells suggesting a non-
specific potency towards any type of cell line (tumorigenic or not).  
To overcome the barrier of non-specific potency, we have developed a novel 
experimental in vitro model of ITC treatment by subjecting human malignant melanoma 
(A375) and non-melanoma (A431) cells as well as human normal keratinocyte (HaCaT; 
control) cells to a range of low ITC concentrations (0.1-5 μM) for 48h, that were refreshed 
after an initial 24h of treatment. Overall, our results highlight the novelty of the in vitro 
experimental model developed not only of being capable in exerting a potent anti-cancer 
activity (at low ITC concentrations) but also of being specific to human malignant melanoma 
(A375) cells while leaving unaffected human non-melanoma (A431) and normal keratinocyte 
(HaCaT) cells. Moreover, our results indicate that BITC (among all the three ITCs) exerts the 
highest anti-cancer potency and thus highlights its effectiveness as a potential anti-cancer 
strategy. 
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Finally, since ITCs have shown to exert a plurality of anti-cancer effects by targeting 
various cellular processes such as, apoptosis, autophagy, cell cycle, angiogenesis, epigenetic 
pathways, antioxidant defenses, etc. (20-28)], we focused on apoptosis in order to elucidate 
which underlined pathways were involved in accounting for the observed reduction of 
viability levels in A375 cells. Overall, ITCs induced apoptosis by activating a number of 
initiator (8, 9, 4) and effector (3, 6, 7) caspases indicating the involvement of various 
apoptotic pathways including but not limited, the extrinsic (caspase 8), intrinsic (caspase 9) 
and ER-dependent (caspase 4) pathways. In our mind, this is the first report that (i) describes 
a novel experimental in vitro model based on the utilization of low ITC concentrations in a 
manner described herein and (ii) how it exerts an anti-cancer effect uniquely to melanoma 
cells (without affecting other non-melanoma and normal keratinocyte cells) by inducing 
apoptosis at concentrations substantially lower than those utilized in current bibliography.   
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Figure Legends 
Figure 1. The effect of different concentrations of ITCs in A375 and HaCaT cells after 24 and 
48h of treatment. Cells were subjected at a single bolus concentration ranging between 5-100 
μΜ of sulforaphane (A; A375 cells and B; HaCaT cells), phenethyl isothiocyanate (C; A375 
cells and D; HaCaT cells) and benzyl isothiocyanate (E; A375 cells and F; HaCaT cells) for 
24 and 48h. Data are representative of two independent experiments. An asterisk (*) or 
hashtag (#) indicates statistical significance when compared to their respective controls 
(DMSO) for 24 or 48h (P<0.05). 
 
Figure 2. The effect of different concentrations of ITCs on HaCaT, A431 and A375 cells after 
48h of treatment. In general, cells were subjected to 0.1-5 μΜ of sulforaphane (A), phenethyl 
isothiocyanate (B) and benzyl isothiocyanate (C) at 0.1-5 μΜ for 48h with all treatments 
being refreshed after 24h. Data are representative from two independent experiments. An 
asterisk (*), hashtag (#) or diamond (◊) indicates statistical significance for HaCaT, A431 or 
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A375 treated cells, respectively when compared to their corresponding controls (DMSO) 
(P<0.05). 
 
Figure 3. The effect of ITCs on enzymatic activity and protein expression levels of various 
caspases. A375 cells were subjected to 5 μM of ITC (for 48h with all treatments being 
refreshed after 24h) and enzymatic activity levels were recorded for caspase 4 (A), caspase 8 
(B) and caspase 9 (C). Additionally, under the same treatment conditions, protein expression 
levels were assessed for procaspase-3 (D), procaspase-6 (E) and procaspase-7 (F). Data are 
representative from two independent experiments. An asterisk (*) indicates statistical 
significance when compared to their respective controls (P<0.05) 
 
 
